Download
tuberculosis haart use and survival in thrio cohort rio de janeiro brazil n.
Skip this Video
Loading SlideShow in 5 Seconds..
Tuberculosis, HAART Use and Survival in THRio Cohort, Rio de Janeiro, Brazil PowerPoint Presentation
Download Presentation
Tuberculosis, HAART Use and Survival in THRio Cohort, Rio de Janeiro, Brazil

Tuberculosis, HAART Use and Survival in THRio Cohort, Rio de Janeiro, Brazil

84 Views Download Presentation
Download Presentation

Tuberculosis, HAART Use and Survival in THRio Cohort, Rio de Janeiro, Brazil

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

  1. Tuberculosis, HAART Use and Survival in THRio Cohort, Rio de Janeiro, Brazil Saraceni V1, King B2, Pacheco AG3, Golub JE2, Cavalcante SC1, Moulton LH2, Moore RD2, Chaisson RE2, Durovni B1 1-Rio de Janeiro City Health Dept., Rio de Janeiro, Brazil; 2 – Johns Hopkins SM, CTBR, Bloomberg SPH, JH HIV Clinic, Baltimore, USA; 3 – DEMQS, Fiocruz, Rio de Janeiro, Brazil Abstract MOAB0305

  2. Background • Questions remain concerning the best time to initiate HAART after TB diagnosis • THRio – Observational cohort study to assess impact of TB screening and INH preventive therapy on TB incidence • Universal access to HAART in Brazil • High TB-burden scenario – common first HIV diagnosis and leading cause of death in HIV patients1 1. Saraceni et al., IJTLD 2008;12:769

  3. Objectives • Compare survival after TB diagnosis in HIV-positive subjects followed at 29 health units in Rio de Janeiro • Comparisons: • exposure to HAART vs. no HAART in the overall group • among those who initiated HAART, timing of initiation of ARV therapy: • Early HAART (<60 days of TB therapy) • Deferred HAART (61-180 days of TB therapy) • Withheld HAART (> 180 days of TB therapy)

  4. Methods • Inclusion Criteria: • First episode of TB diagnosed from 01 Sep 2003 to 30 Jun 2006 • HIV diagnosed either before or after TB • Right censored at last note in chart or 31 Dec 2006 • Mortality data available through State surveillance system up to 31 Dec 2006 • Statistical Analysis: • Descriptive statistics • Kaplan-Meier estimates • Cox proportional hazards regression models

  5. Results • At time of this analysis: • 15,426 HIV+ patients receiving care in Rio City clinics • 963 (6%) new TB cases diagnosed from 01 Sep 2003 to 30 Jun 2006 • 632 (66%) patients were HAART-naive at time of TB diagnosis • 459 (73%) started HAART in the follow-up period • 85/632 TB patients (13%) died during follow up

  6. Table 1 – Characteristics of subjects by survival status

  7. Table 2 – Characteristics of subjects by exposure to HAART

  8. Table 3 – Characteristics of subjects by timing of exposure to HAART

  9. Table 4 – Time to HIV diagnosis after TB episode among those exposed to HAART

  10. Graph 1 – Kaplan-Meier: Survival After a TB diagnosis, by exposure to HAART Log-rank test – p<.001

  11. Graph 2 – Kaplan-Meier: Survival After a TB diagnosis, by completion of TB treatment Log-rank test – p<.001

  12. Graph 3 – Kaplan-Meier: Survival After a TB diagnosis, by completion of TB treatment, of those who survived longer than 180 days Log-rank test – p<. 001

  13. Graph 4– Kaplan-Meier: Survival After a TB diagnosis, by CD4 category Log-rank test – p=.985

  14. Graph 5 – Kaplan-Meier: Survival After a TB diagnosis, by timing of TB and HIV diagnosis Log-rank test – p=.018

  15. Graph 6 – Kaplan-Meier: Time to HAART: <=60, 61-180 or > 180 days after TB treatment started Log-rank test – p=.306

  16. Table 5: Cox model – Univariate analysis, all cases

  17. Table 6: Final Cox model, all cases

  18. Conclusions • HAART exposure significantly related to improved survival after TB diagnosis (univariate HR=0.30; aHR=0.48) • The benefits of HAART were found despite lower median CD4 counts in those who received it vs. those who did not • Time of initiation of HAART not associated with significant changes in survival • Delays in diagnosis HIV in TB patients associated with lower likelihood of receiving HAART • Universal opt-out testing for all TB patients essential